$18.04
-0.01-0.06%
In chiusura: -
$17.94
-0.10-0.57%
After hour: 4:19 PM EDT
Comments
Loading...
Guidance e previsioni
Teva Pharmaceutical Indus fornisce indicazioni su EPS e ricavi futuri, offrendo agli investitori informazioni su quanto la società prevede di guadagnare nei prossimi periodi.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
07/30/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.50 | $2.60 | $2.50 | $16.80B | $17.20B | $16.97B | |
05/07/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.45 | $2.65 | $2.56 | $16.80B | $17.20B | $17.24B | |
03/27/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.35 | $2.65 | $2.54 | $16.80B | $17.40B | $17.14B | |
03/27/2025 | TEVA | Teva Pharmaceutical Indus | Q1 | 2025 | $0.52 | $0.52 | $0.48 | $3.99B | $3.99B | $3.98B | |
01/29/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.35 | $2.65 | $2.78 | $16.80B | $17.40B | $17.09B | |
11/06/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.40 | $2.50 | $2.45 | $16.10B | $16.50B | $16.26B | |
07/31/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.30 | $2.50 | $2.34 | $16.00B | $16.40B | $16.01B | |
05/08/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.20 | $2.50 | $2.41 | $15.70B | $16.30B | $15.86B | |
01/31/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.20 | $2.50 | $2.42 | $15.70B | $16.30B | $15.57B | |
11/08/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.28 | $15.10B | $15.50B | $15.14B | |
08/02/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.27 | $15.00B | $15.40B | $15.02B | |
05/10/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.40 | $14.80B | $15.40B | $15.06B | |
02/08/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.52 | $14.80B | $15.40B | $15.23B | |
11/03/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | $2.50 | $14.80B | $15.40B | $15.46B | |
07/26/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | — | $15.00B | $15.60B | $15.67B | |
05/03/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | $2.51 | $15.40B | $16.00B | $15.97B | |
02/09/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | $2.64 | $15.60B | $16.20B | $16.32B | |
10/27/2021 | TEVA | Teva Pharmaceutical Indus | FY | 2021 | $2.50 | $2.70 | $2.58 | $16.00B | $16.40B | $16.30B | |
07/28/2021 | TEVA | Teva Pharmaceutical Indus | FY | 2021 | $2.50 | $2.70 | $2.45 | $16.00B | $16.40B | $16.55B | |
04/28/2021 | TEVA | Teva Pharmaceutical Indus | FY | 2021 | $2.50 | $2.70 | $2.61 | $16.40B | $16.80B | $16.68B | |
02/10/2021 | TEVA | Teva Pharmaceutical Indus | FY | 2021 | $2.50 | $2.70 | $2.63 | $16.40B | $16.80B | $16.76B |
FAQ
Qual è la guidance più recente per Teva Pharmaceutical Indus (TEVA)?
Le ultime previsioni per Teva Pharmaceutical Indus (TEVA) sono state riportate il luglio 30, 2025 per l'intero anno 2025. L'azienda ha fornito una previsione di utili per azione nell'intervallo da $2.50 a $2.60, rispetto all'EPS stimato di $2.50. Inoltre, Teva Pharmaceutical Indus ha previsto ricavi tra $16.80B e $17.20B per il trimestre.
Sfoglia guidance e previsioni su tutte le azioni.